News from Cytotheryx

Receive the Latest News from Us

Medical breakthroughs require innovative solutions, and Cytotheryx delivers. Learn more about our work from our latest news and updates.

Overview

Cytotheryx is a platform technology company solving for the limited supply of primary human hepatocytes currently used in drug discovery and disease-specific research, and supporting the development of new therapeutics for liver failure, liver disease, and rare diseases. We look forward to opportunities to share more about our work — and its benefits — with the life science community.

Contact Us

Looking for more information on our work? Get in touch with us. We’re always happy to discuss potential opportunities.

Anna Argo, Director of Business Development
Tel: +1 (877) 275 2986
Email: anna.argo@cytotheryx.com

Read Our Latest Updates

Covid-19 Statement

We are committed to our work and the wellness of our communities, and will remain so during this challenging and uncertain time of COVID-19.

Cytotheryx Achieves Full AAALAC International Accreditation

Cytotheryx received a full AAALAC International accreditation, the highest certification level. Learn what this accreditation means and how we achieved it.

Cytotheryx Receives 2022 BOLD Award

The Cytotheryx team is humbled and honored to have been selected as a 2022 Early Stage BOLD Award Winner at the 10th Annual BOLD Awards!

Featuring Cytotheryx in Your Work?

Reach out to us! We’re open to conversations about our work, liver disease, and how a consistent, high-quality source of primary human hepatocytes will revolutionize the biomedical field as we know it.